恒瑞医药：注射用瑞康曲妥珠单抗纳入突破性治疗品种名单

Core Viewpoint - The announcement highlights that the company's subsidiary, Suzhou Merrion Biopharmaceutical Co., Ltd., has received a breakthrough therapy designation from the National Medical Products Administration for its injectable SHR-A1811, marking the tenth indication for this drug to achieve such recognition [1] Group 1 - The injectable SHR-A1811 has been included in the list of breakthrough therapies by the National Medical Products Administration [1] - This designation signifies a significant milestone for the company, as it reflects the potential of SHR-A1811 in treating specific medical conditions [1] - The achievement of ten breakthrough therapy certifications for SHR-A1811 indicates the drug's promising therapeutic profile and the company's commitment to advancing its development [1]